Market Context — Why This Technology, Why Now

The global shift towards precision medicine and personalized therapies is driving demand for highly targeted drug delivery systems that minimize systemic side effects. Regulatory bodies are increasingly scrutinizing drug safety and efficacy, pushing for innovations that improve therapeutic ratios. This technology offers a competitive edge by enabling precise drug targeting, potentially unlocking new treatments for intractable diseases like Alzheimer's and various cancers, where current delivery methods are insufficient. It aligns with the imperative to reduce healthcare costs by optimizing drug dosage and improving patient outcomes.

Key Competitive Advantages
01

Achieves highly efficient targeted drug delivery by precisely opening blood vessel walls with negative pressure focused ultrasound, maximizing drug delivery efficiency while minimizing systemic impact.

02

Significantly reduces side effect risks by potentially reducing drug dosage, thereby substantially lowering systemic side effect risks and improving patient quality of life.

03

Offers a new approach for intractable disease treatment by safely opening the blood-brain barrier and tumor neovasculature, providing new therapeutic options for previously challenging brain diseases and cancers.

Market Opportunity
Neurological Disorder Treatment
$3.5B globally (AI est.)
This technology could offer groundbreaking efficacy in treating diseases where the blood-brain barrier (BBB) impedes drug delivery, such as Alzheimer's and Parkinson's disease. With an increasing patient population, developing new treatment methods is critical.
Pharmaceutical companies developing CNS drugs Medical device manufacturers for neuro-interventions Biotech firms focused on brain disorders
Cancer Therapy
$13.5B globally (AI est.)
In cancer chemotherapy, this technology has the potential to enhance the permeability of tumor neovasculature and augment the EPR effect, improving anti-cancer drug delivery to tumors and overall treatment efficacy. It could also contribute to reducing side effects.
Oncology pharmaceutical companies Medical imaging and therapy device developers Biotech firms specializing in targeted cancer therapies
Regenerative Medicine & Gene Therapy
$650M globally (AI est.)
This technology could be applied as a localized permeability enhancement technique in fields requiring efficient delivery to specific cells or tissues, such as stem cells and gene therapy agents.
Regenerative medicine companies Gene therapy developers Cell therapy research institutions
Aesthetic Medicine
$2.5B domestically (AI est.)
This technology could facilitate the deeper penetration of cosmetic ingredients and pharmaceuticals into the skin, enabling more effective skincare and anti-aging treatments. It has the potential to open new market segments for aesthetic devices.
Cosmeceutical companies Aesthetic device manufacturers Dermatology clinics and research centers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

The patent was granted after a single office action, with appropriate amendments and arguments, indicating a robust and valid scope of claims. With 4 claims, the patent protects the core mechanism of generating negative pressure focused ultrasound for enhancing vascular permeability, demonstrating high originality against limited prior art.

Competitive White Space

This patent focuses on negative pressure focused ultrasound for vascular permeability. White space exists in integrating this with advanced imaging for real-time feedback or exploring non-drug therapeutic applications, such as localized nutrient delivery or cosmetic treatments.

Economic Impact
~$6.5M/year estimated healthcare cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming a domestic annual cancer drug market of ~$6.5B (AI est.), this technology could improve drug delivery efficiency by 20% and reduce high-cost drug dosage by 10%. This could lead to an estimated annual treatment cost reduction of ~$6.5M (AI est.) within a ~$65M (AI est.) treatment cost market. Further economic impact is expected from improved treatment success rates, reduced recurrence, and shorter hospital stays.

Speed to Market
3× faster than in-house development
This technology has already demonstrated proof-of-concept at the prototype stage, with key technical challenges resolved. The principle of negative pressure focused ultrasound generation is established, and basic safety evaluations are presumed to be underway. Therefore, adopting this technology could significantly shorten development timelines. With principle verification complete, it can directly lead to application development for commercialization, potentially reducing time-to-market by approximately 3.5 years.
Competitive Positioning

X: Precision of Therapeutic Effect
Y: Reduction in Patient Burden

Business Models & Applications
🏥 Medical Device OEM/ODM
Develop medical devices incorporating this technology and supply them to existing medical device manufacturers via OEM/ODM, contributing to product line expansion and market share growth.
💊 Co-development with Therapeutics
Collaborate with specific therapeutic drug manufacturers to co-develop drug delivery systems using this technology, maximizing drug value and creating new treatment methods.
🤝 Licensing Model
Grant licenses for this technology to research institutions and companies in other industries, beyond the medical field, to expand its utilization across various sectors and monetize the IP.
Adjacent Application Opportunities
🔬 Research & Analysis
Cell & Tissue Permeability Control Tool
Offer as a negative pressure ultrasound permeability control device for research into substance permeation mechanisms at the biological tissue and cellular level. This could streamline basic research and facilitate new discoveries, potentially accelerating research timelines by 20-30%.
🧪 Drug Discovery
Novel Drug Delivery System (DDS) Development
Apply as a specialized DDS to improve in-vivo absorption and distribution of poorly soluble or macromolecular drugs. This could maximize the potential of existing drugs and increase the success rate of new drug development by an estimated 15-25%.
👩‍⚕️ Regenerative Medicine
Localized Stem Cell & Gene Delivery Support
Utilize as an auxiliary device in regenerative medicine for efficient and minimally invasive delivery of stem cells or gene therapy agents to specific affected areas or organs. This could enhance treatment efficacy by up to 30% and reduce patient burden.
Integration Roadmap — Estimated 36-Month Deployment
Phase 1: Technology Evaluation & Prototype Verification
Duration: 6 months
Conduct detailed technical evaluation of this technology and assess its integration potential into existing ultrasound devices. Perform performance evaluation of prototypes and initial biocompatibility tests to establish a foundation for clinical application.
Phase 2: Pre-clinical Development & Device Optimization
Duration: 12 months
Execute animal studies to evaluate drug delivery efficiency and safety. Based on results, proceed with device design optimization, control algorithm refinement, and design review for mass production.
Phase 3: Regulatory Approval Preparation & Market Launch
Duration: 18 months
Develop clinical trial plans, consult with regulatory authorities, and prepare for regulatory approval applications. After approval, initiate deployment to medical institutions and market expansion, aiming for widespread adoption through partnerships.
Technical Feasibility
This technology is based on relatively common ultrasound device components such as piezoelectric material sound wave generation elements, pulsed voltage generators, and focusing elements. Specifically, by controlling the polarity of the pulsed voltage to generate negative pressure focused ultrasound, it could be integrated without major hardware changes to existing ultrasound diagnostic and therapeutic devices, potentially through software optimization and specific component replacement. Therefore, the technical hurdles are considered relatively low.
Success Scenario
If this technology is adopted, the efficiency of anti-cancer drug delivery to tumors could potentially double compared to current methods. This is estimated to achieve equivalent or superior therapeutic effects while reducing drug dosage by 20%. Consequently, patient side effect risks could be lowered, and total healthcare costs could be reduced by several million dollars annually (AI est.). Furthermore, it may enable brain delivery of dementia drugs, offering new treatment options for previously challenging diseases.
Patent Record
APPLICATION NO.
特願2023-112455
REGISTRATION NO.
7572744
FILING DATE
2023/07/07
GRANT DATE
2024/10/16
EXPIRATION DATE
2043/07/07
PATENT HOLDER
有限会社ユーマンネットワーク
Examination History
2023年07月13日
出願審査請求書
2024年07月09日
拒絶理由通知書
2024年07月30日
手続補正書（自発・内容）
2024年07月30日
意見書
2024年10月01日
特許査定